NEW YORK (GenomeWeb News) – Epigenomics today reported a 67 percent drop year over year in first-quarter revenues.

For the three months ended March 31, the German molecular diagnostics firm reported €200,000 ($258,892) in revenues, down from €600,000 a year ago, when it received a payment from Qiagen for a non-exclusive license to Epigenomics' methylated Septin-9 biomarker.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.